Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avadel Pharmaceuticals ( (AVDL) ) has issued an announcement.
On July 29, 2025, Avadel Pharmaceuticals held its Annual Meeting of Shareholders where a quorum was established with 83,659,463 shares represented. The meeting resulted in the election of seven directors to the Board for a one-year term and the ratification of Deloitte & Touche LLP as the company’s independent auditor for the fiscal year ending December 31, 2025. These decisions are expected to impact the company’s governance and financial oversight positively.
The most recent analyst rating on (AVDL) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Avadel Pharmaceuticals stock, see the AVDL Stock Forecast page.
Spark’s Take on AVDL Stock
According to Spark, TipRanks’ AI Analyst, AVDL is a Neutral.
Avadel Pharmaceuticals’ overall stock score reflects robust growth potential driven by strong product adoption and strategic corporate developments. However, ongoing profitability challenges and valuation concerns limit the upside. Technical momentum provides a positive outlook, but investors should be cautious of overbought signals.
To see Spark’s full report on AVDL stock, click here.
More about Avadel Pharmaceuticals
Avadel Pharmaceuticals plc operates in the pharmaceutical industry, focusing on developing and commercializing innovative medicines. The company is known for its efforts in addressing unmet medical needs, particularly in the realm of sleep disorders and other therapeutic areas.
Average Trading Volume: 1,387,823
Technical Sentiment Signal: Buy
Current Market Cap: $1.05B
For a thorough assessment of AVDL stock, go to TipRanks’ Stock Analysis page.